Cannabis-based products will be allowed to bypass usual
processes required for medicines in New Zealand and go
directly onto the market without any proof of safety or
effectiveness. This unprecedented proposal is contained in
the government’s consultation document on giving greater
access to medicinal cannabis.
The government is
introducing a scheme for regulating medicinal
cannabis. The consultation covers proposed licensing,
cultivation, manufacturing and product standards, and a
prescription and enforcement regime.
The key driver for
this seems to be that people currently access cannabis
through the illegal recreational market. But even if there
is no doubt that a regulated market would provide a safer
environment for access, we argue that there could be a
potential cost to patient safety.
From trial to
The usual market pathway for a drug in…